These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 26774951)

  • 1. Angina and associated healthcare costs following percutaneous coronary intervention: A real-world analysis from a multi-payer database.
    Ben-Yehuda O; Kazi DS; Bonafede M; Wade SW; Machacz SF; Stephens LA; Hlatky MA; Hernandez JB
    Catheter Cardiovasc Interv; 2016 Dec; 88(7):1017-1024. PubMed ID: 26774951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thirty-Day Readmission Rate and Costs After Percutaneous Coronary Intervention in the United States: A National Readmission Database Analysis.
    Tripathi A; Abbott JD; Fonarow GC; Khan AR; Barry NG; Ikram S; Coram R; Mathew V; Kirtane AJ; Nallamothu BK; Hirsch GA; Bhatt DL
    Circ Cardiovasc Interv; 2017 Dec; 10(12):. PubMed ID: 29246918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs Associated With Access Site and Same-Day Discharge Among Medicare Beneficiaries Undergoing Percutaneous Coronary Intervention: An Evaluation of the Current Percutaneous Coronary Intervention Care Pathways in the United States.
    Amin AP; Patterson M; House JA; Giersiefen H; Spertus JA; Baklanov DV; Chhatriwalla AK; Safley DM; Cohen DJ; Rao SV; Marso SP
    JACC Cardiovasc Interv; 2017 Feb; 10(4):342-351. PubMed ID: 28231901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the Healthcare Value of Percutaneous Coronary Intervention: Appropriateness, Outcomes, and Costs in Michigan Hospitals.
    Alyesh DM; Seth M; Miller DC; Dupree JM; Syrjamaki J; Sukul D; Dixon S; Kerr EA; Gurm HS; Nallamothu BK
    Circ Cardiovasc Qual Outcomes; 2018 Jun; 11(6):e004328. PubMed ID: 29853465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness of Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease and Acute Coronary Syndromes in the US Medicare Program.
    Reynolds MR; Gong T; Li S; Herzog CA; Charytan DM
    J Am Heart Assoc; 2021 Apr; 10(7):e019391. PubMed ID: 33787323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resource consumption and healthcare costs of acute coronary syndrome: a retrospective observational administrative database analysis.
    Roggeri A; Gnavi R; Dalmasso M; Rusciani R; Giammaria M; Anselmino M; Roggeri DP
    Crit Pathw Cardiol; 2013 Dec; 12(4):204-9. PubMed ID: 24240551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence, Predictors, and Outcomes of Acute Ischemic Stroke Following Percutaneous Coronary Intervention.
    Alkhouli M; Alqahtani F; Tarabishy A; Sandhu G; Rihal CS
    JACC Cardiovasc Interv; 2019 Aug; 12(15):1497-1506. PubMed ID: 31395220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial.
    Arnold SV; Morrow DA; Lei Y; Cohen DJ; Mahoney EM; Braunwald E; Chan PS
    Circ Cardiovasc Qual Outcomes; 2009 Jul; 2(4):344-53. PubMed ID: 20031860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for patients with 3-vessel or left main coronary artery disease: final results from the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) trial.
    Cohen DJ; Osnabrugge RL; Magnuson EA; Wang K; Li H; Chinnakondepalli K; Pinto D; Abdallah MS; Vilain KA; Morice MC; Dawkins KD; Kappetein AP; Mohr FW; Serruys PW;
    Circulation; 2014 Sep; 130(14):1146-57. PubMed ID: 25085960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resource Utilization and Costs Associated With Percutaneous Coronary Intervention When Treating Patients With Acute Coronary Syndrome in the Mexican National Institute of Cardiology "Ignacio Chávez".
    Jones K; Ramirez J; Papadimitropoulos M; Lomelí OS; Vanegas HR; Cortina de la Rosa E; Izaguirre Ávila R
    Value Health Reg Issues; 2019 Dec; 20():136-141. PubMed ID: 31419609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bivalirudin is associated with improved clinical and economic outcomes in heart failure patients undergoing percutaneous coronary intervention: Results from an observational database.
    Pinto DS; Kohli P; Fan W; Kirtane AJ; Kociol RD; Meduri C; Deliargyris EN; Prats J; Reynolds MR; Stone GW; Michael Gibson C
    Catheter Cardiovasc Interv; 2016 Feb; 87(3):363-73. PubMed ID: 26011467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic impact of same-day home discharge after uncomplicated transradial percutaneous coronary intervention and bolus-only abciximab regimen.
    Rinfret S; Kennedy WA; Lachaine J; Lemay A; Rodés-Cabau J; Cohen DJ; Costerousse O; Bertrand OF
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1011-9. PubMed ID: 20965458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of percutaneous coronary intervention versus bypass surgery from a Dutch perspective.
    Osnabrugge RL; Magnuson EA; Serruys PW; Campos CM; Wang K; van Klaveren D; Farooq V; Abdallah MS; Li H; Vilain KA; Steyerberg EW; Morice MC; Dawkins KD; Mohr FW; Kappetein AP; Cohen DJ;
    Heart; 2015 Dec; 101(24):1980-8. PubMed ID: 26552756
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Persistent Angina After Myocardial Infarction Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study.
    Fanaroff AC; Kaltenbach LA; Peterson ED; Hess CN; Cohen DJ; Fonarow GC; Wang TY
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29051217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical and cost burden of coronary calcification in a Medicare cohort: An economic model to address under-reporting and misclassification.
    Garrison LP; Lewin J; Young CH; Généreux P; Crittendon J; Mann MR; Brindis RG
    Cardiovasc Revasc Med; 2015; 16(7):406-12. PubMed ID: 26361178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention.
    Dong OM; Wheeler SB; Cruden G; Lee CR; Voora D; Dusetzina SB; Wiltshire T
    Value Health; 2020 Jan; 23(1):61-73. PubMed ID: 31952675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1-year risk-adjusted mortality and costs of percutaneous coronary intervention in the Veterans Health Administration: insights from the VA CART Program.
    Ho PM; O'Donnell CI; Bradley SM; Grunwald GK; Helfrich C; Chapko M; Liu CF; Maddox TM; Tsai TT; Jesse RL; Fihn SD; Rumsfeld JS
    J Am Coll Cardiol; 2015 Jan; 65(3):236-42. PubMed ID: 25614420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and economic outcomes among elderly myocardial infarction survivors in the United States.
    Yang E; Stokes M; Johansson S; Mellström C; Magnuson E; Cohen DJ; Hunt P
    Cardiovasc Ther; 2016 Dec; 34(6):450-459. PubMed ID: 27564212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contemporary trend of acute kidney injury incidence and incremental costs among US patients undergoing percutaneous coronary procedures.
    Prasad A; Rosenthal NA; Kartashov A; Knish K; Dreyfus J
    Catheter Cardiovasc Interv; 2020 Nov; 96(6):1184-1197. PubMed ID: 32129574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct healthcare costs and resource consumption after acute coronary syndrome: a real-life analysis of an Italian subpopulation.
    Roggeri DP; Roggeri A; Rossi E; Cinconze E; De Rosa M; Maggioni AP;
    Eur J Prev Cardiol; 2014 Sep; 21(9):1090-6. PubMed ID: 23515447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.